On Jan. 11, 2021, TheNew York Times posted an article about the virtues of fecal immunochemical testing relative to colonoscopy. The story, “A Colonoscopy Alternative Comes Home” [https://www.nytimes.com/ 2021/ 01/ 11/ health/ colonoscopy-health-home-testing.html] depicted colonoscopy as a comparatively risky procedure with few advantages over less invasive methods of testing for colorectal cancer. It also offered the speculation that financial factors— namely, greater reimbursement for endoscopy—was behind the general preference of gastroenterologists for colonoscopy over stool tests.
Trending
- Experts weigh in on liability over AI use in healthcare (Healio)
- Ascension’s Outpatient Surgery Volume Rose Nearly 400% After AMSURG Buy (ASC News)
- CMS Finalizes Reassignment of Gastric Alimetry® Test to Higher Payment Level, Increasing Medicare Hospital Outpatient Payment by Approximately 144% (Globe Newswire )
- MedInTech Secures $25.7 Million for AI Robotics Expansion (DistilINFO)
- AI-assisted colonoscopy and disease-specific imaging show benefits in ulcerative colitis (Hospital Healthcare Europe)
- The race to understand why young people are dying from colon cancer (Scientific American)
- What the Robot Still Can’t Do (NEJM)
- Geneoscopy Resolves Patent and False Advertising Litigation with Exact Sciences Following a Series of Victories at the Patent Trial and Appeal Board (PR Newswire)
